Full clinical trial not needed for Parkinson’s drug patent, IP Australia says
Healthcare 2022-05-24 12:32 pm By Sam Matthews Melbourne
Please login to bookmark Close

An IP Australia delegate has rejected German drug maker Ever Neuro Pharma’s claim that extensive experimental evidence was needed to prove the usefulness of a Parkinson’s drug developed by UK-based Britannia Pharmaceuticals.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au